Abstract

Dementia-related diseases like Alzheimer's Disease (AD) have a tremendous social and economic cost. A deeper understanding of its underlying pathophysiologies may provide an opportunity for earlier detection and therapeutic intervention. Previous approaches for characterizing AD were targeted at single aspects of the disease. Yet, due to the complex nature of AD, the success of these approaches was limited. However, in recent years, advancements in integrative disease modeling, built on a wide range of AD biomarkers, have taken a global view on the disease, facilitating more comprehensive analysis and interpretation. Integrative AD models can be sorted in two primary types, namely hypothetical models and data-driven models. The latter group split into two subgroups: (i) Models that use traditional statistical methods such as linear models, (ii) Models that take advantage of more advanced artificial intelligence approaches such as machine learning. While many integrative AD models have been published over the last decade, their impact on clinical practice is limited. There exist major challenges in the course of integrative AD modeling, namely data missingness and censoring, imprecise human-involved priori knowledge, model reproducibility, dataset interoperability, dataset integration, and model interpretability. In this review, we highlight recent advancements and future possibilities of integrative modeling in the field of AD research, showcase and discuss the limitations and challenges involved, and finally, propose avenues to address several of these challenges.

Highlights

  • Alzheimer’s Disease (AD) manifests in a collection of symptoms including the deterioration of cognition, memory, and behavior which often leads to interference with activities of daily living

  • We have reviewed a broad variety of data-driven integrative AD models and elaborated on their associated limitations and challenges

  • Several large-scale AD patient datasets have been collected for use in a variety of studies (Lawrence et al, 2017) including, for example, Alzheimer’s Disease Neuroimaging Initiative (ADNI; Mueller et al, 2005), Australian Imaging Biomarkers and Lifestyle Study of Aging (AIBL; Ellis et al, 2009), the Dominantly Inherited Alzheimer Network (DIAN; Moulder et al, 2013), and European Prevention of Alzheimer’s Dementia (EPAD; Vermunt et al, 2018)

Read more

Summary

INTRODUCTION

Alzheimer’s Disease (AD) manifests in a collection of symptoms including the deterioration of cognition, memory, and behavior which often leads to interference with activities of daily living. Understanding of the etiology of AD is complicated due to the existence of dysregulations at different biological scales, ranging from genetic mutations to structural and functional alterations of the brain (Aisen et al, 2017) For this reason, significant efforts have been made in recent years to discover candidate markers for disease-related pathological changes throughout all modalities, including neuro-imaging, cerebrospinal fluid (CSF) samples and a broad variety of -omics data. A new translational research paradigm called “integrative disease modeling” has emerged, to address this challenge (Younesi and Hofmann-Apitius, 2013) It aims at modeling heterogeneous measurements across different biological scales, in order to provide a holistic picture of biomarker intercorrelations in the disease of study. To this end, advanced high-throughput technologies and neuroimaging procedures are being used to collect data from multiple modalities.

Machine learning
INTEGRATIVE AD MODELS
Hypothetical Models
Challenges of Hypothetical Models
Findings
CONCLUSION
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.